NCT00117663

Brief Summary

The purpose of this study is to determine whether cessation of hormone replacement therapy for one or two months before a screening mammogram will improve its performance by decreasing breast density.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,704

participants targeted

Target at P75+ for not_applicable breast-cancer

Timeline
Completed

Started Nov 2004

Typical duration for not_applicable breast-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2004

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

June 30, 2005

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 8, 2005

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2007

Completed
16.4 years until next milestone

Results Posted

Study results publicly available

April 4, 2024

Completed
Last Updated

April 4, 2024

Status Verified

March 1, 2024

Enrollment Period

3 years

First QC Date

June 30, 2005

Results QC Date

February 3, 2016

Last Update Submit

March 28, 2024

Conditions

Keywords

Randomized controlled trialMammographyhealth care settinghormone replacement therapybreast densitymammography performanceBreast Carcinoma

Outcome Measures

Primary Outcomes (2)

  • Mammogram Recall for Additional Imaging

    Mammography recall was defined as any assessment requiring additional imaging or evaluation of either breast (BI-RADS assessment of 0 for either or both breasts)(30) determined exclusively from the study radiologists' interpretation.

    4 years

  • Mammographic Breast Density

    Breast density (Mean, SE) and Change in Breast density by Randomization Group

    4 years

Study Arms (3)

No Hormone Suspension

NO INTERVENTION

No hormone suspension prior to screening mammogram

1 month hormone suspension

ACTIVE COMPARATOR

discontinuation of hormone therapy for 1 month prior to screening mammogram.

Other: temporary discontinuation of hormone therapy for 1 month

2 month hormone suspension

ACTIVE COMPARATOR

discontinuation of hormone therapy for 2 months prior to screening mammogram.

Other: temporary discontinuation of hormone therapy for 2 months

Interventions

temporary discontinuation of hormone replacement therapy for 1 month prior to screening mammogram.

1 month hormone suspension

temporary discontinuation of hormone replacement therapy for 2 months prior to screening mammogram

2 month hormone suspension

Eligibility Criteria

Age45 Years - 80 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • or more prior screening mammograms at Group Health Cooperative within the past 2 years
  • Currently taking HRT
  • Taking HRT at prior screening mammogram
  • Due for a screening mammogram

You may not qualify if:

  • BI-RADS breast density of 1 (entirely fat)
  • Previous cardiovascular events (heart surgery, catheterization, stent bypass, angioplasty, stroke, DVT)
  • Previous breast cancer
  • History of breast implants
  • Breast reduction since last mammogram
  • Mastectomy
  • History of using Tamoxifen or Raloxifene
  • Declined contact or use of data for research

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Group Health Research Institute

Seattle, Washington, 98101, United States

Location

Related Publications (4)

  • Lowry SJ, Aiello Bowles EJ, Anderson ML, Buist DS. Predictors of breast density change after hormone therapy cessation: results from a randomized trial. Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2309-12. doi: 10.1158/1055-9965.EPI-11-0629. Epub 2011 Aug 3.

  • Newton KM, Anderson ML, Reed SD, Bowles EJ, Buist DS. Factors associated with non-compliance with hormone therapy cessation before screening mammography. Climacteric. 2011 Apr;14(2):268-74. doi: 10.3109/13697137.2010.520172. Epub 2010 Oct 27.

  • Aiello Bowles EJ, Anderson ML, Reed SD, Newton KM, Fitzgibbons ED, Seger D, Buist DS. Mammographic breast density and tolerance for short-term postmenopausal hormone therapy suspension. J Womens Health (Larchmt). 2010 Aug;19(8):1467-74. doi: 10.1089/jwh.2009.1681.

  • Reed SD, Buist DS, Anderson ML, Bowles EJ, Fitzgibbons D, Seger D, Newton KM. Short-term (1-2 mo) hormone therapy cessation before mammography. Menopause. 2009 Nov-Dec;16(6):1125-31. doi: 10.1097/gme.0b013e3181a5ce60.

Related Links

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Results Point of Contact

Title
Diana Buist PhD, Principal Investigator
Organization
Group Health Research Institute

Study Officials

  • Diana SM Buist, Ph.D.

    Kaiser Permanente

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 30, 2005

First Posted

July 8, 2005

Study Start

November 1, 2004

Primary Completion

November 1, 2007

Study Completion

November 1, 2007

Last Updated

April 4, 2024

Results First Posted

April 4, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations